More Thom Calandra comments: * IMV Inc.: Next week will mark a landmark event for the cancer treatment developer. SOLO THERAPY DPX-Survivac topline results. Sell-side analysts mixing with scientists and execs in NYC two days after that. Most of you know how committed I have been to the Halifax immunotherapy developer. Five years come June. Some I know, several subscribers and intuits, who own 10 to 20 times our 144,000 IMV shares, and they have been involved as board members, financiers and patient fund managers for six-plus years, 9 years, 16 years. Boris Cukon in Antwerp; Wade Dawe in Halifax; Albert Scardino in London. Also, at my smaller-fry level (144,000 shares worth approx $695,000 USD), 15 or so years-long The Calandra Report/TCR subscribers who hail from Montral, from Germany, from Boston, San Francisco, Toronto, Kelowna, Ottawa, all of these individuals in for their respective 20,000-plus share counts over the years).
When a biomedical stock that is attached to a pioneering approach, at a time when its subject, cancer, is a headline-making topic planetary, breaks through and starts to reflect the science that has cost $50 million, $100 million, to develop, well, life gets a slap on the back. IMV (please go through some of the five years of coverage at The Calandra Report/TCR)will show what I think will be some of the most potent T-cell activation data existing in the crowded field of oncology. Next week.
Frederic Ors, IMV CEO The laboratory’s methodology I believe will apply to many cancers that express survivin, and some that don’t. Also infectious diseases across the board. This company is still obscure; still less than a $250 million USD market value; still pre-FDA approval for any of its formulations; still pre-breakthrough status for its therapies via Food & Drug Administration; and still without a pharma partner to bankroll commercial testing for ovarian cancer treatments, possibly DLBCL lymphoma treatments, possibly non-small-cell lung cancer treatments, and more.
At some point soon, IMV and its way of delivering therapies into the body, its no-release mechanism of action, will reach the front page, maybe even of The New York Times. That’s me talking. Clearly, I am hoping so for the sake of patients in these regulated clinical trials across a range of killing cancers.
The rebounding and now active IMV stock (NASDAQ and TORONTO) is all over the place, and I say hesitantly, taking a one-day breather from a non-stop run higher this year and late last year.
When IMV in USD gets to that one-year high of $5.11 USD or so from winter 2019, and stays there, the stock will levitate to $10, and then to $20 and beyond. There are two dozen “immuno-therapy” companies in five countries that are $2 billion market values, yet having a FIFTH or a TENTH of what IMV has in its data, its owned and licensed and patented antigens and delivery methods, its partnerships (Leidos, the D.C.- area health care defense think tank, is one that gets little heed regarding pandemics), and in its medical and scientific talent.
Listen to what Oliver Dorigo, a Stanford University scientist and researcher on the ovarian cancer beat, has to say next week in the web cast Tuesday: https://ir.imv-inc.com/news-releases/news-release-details/imv-host-conference-call-webcast-report-updated-results-decide1.
I added yet again to our holdings (Friday) at $4.62 USD and $4.80 USD. The shares tend to close strongly these days. Whether the $5-plus happens at Friday’s close (it got there, then retreated) or in Tuesday’s pre-market, or when the nine analysts who track IMV update their research later in the week, means just a little to me. I am confident this is a billion-dollar-plus opportunity, my next Illumina (when that one 17 years ago was a $250 million market value).
On Thursday February 27, 2020, company and academic scientists leading these ovarian cancer studies, including Dr. Oliver Dorigo, will analyze why survivin is so important as a target for IMV therapies. So: DPX-Survivac. We all will, I think, and pray, be hearing and reading and seeing more about the approach and its no-release mechanism of actionto reach tumors.
IMV Probables:
- Efficacy data on Tuesday February 25, declaring the ovarian cancer solo therapy (no Keytruda in this one) trial has met its end points;
- as many as 9 analysts publishing on Wednesday or Thursday bto say what they think;
- scientists at NYC gathering talking to say why this particular protein, survivin, is important as a target; finally, while there is no finally, DPX-Survivac “basket” results pointed to for June 2020, possibly at ASCO annual meeting Chicago. Thus, this week’s looming ovarian Phase II top-line human results likely will foreshadow cancer-basket studies of patients with 5 indications of disease, including non-small-cell lung cancer.